Company: MDCXW
Filing Date: 2025-05-27
Form Type: S-1
Source: 0001062993-25-010394
Chunk: 235

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-27
Form: S-1
Chunk 235
---
 |   |                              |   |   |            |   |
| Net proceeds from issuance of common shares and warrants in connection with Regulation A |   |                    3,784,101 |   |   |          - |   |
| Cash paid for financing costs in connection with SEPA                                    |   |                      (25,000 | ) |   |          - |   |
| Net cash provided by financing activities                                                |   |                    3,759,101 |   |   |          - |   |
| Net decrease in cash and cash equivalents during the period                              |   |                     (181,893 | ) |   | (1,176,933 | ) |
| Cash and cash equivalents, beginning of the year                                         |   |                    4,164,323 |   |   |  1,719,338 |   |
| Cash and cash equivalents, end of the year                                               | $ |                    3,982,430 |   | $ |    542,405 |   |
| Supplemental disclosure of non-cash investing and financing activities                   |   |                              |   |   |            |   |
| Right-of-use assets obtained in exchange for lease liabilities                           | $ |                            - |   | $ |    356,805 |   |
| Receivable for proceeds of warrant exercises                                             | $ |                       14,000 |   | $ |          - |   |
| Issuance costs included in accounts payable                                              | $ |                       95,120 |   | $ |          - |   |
| Deferred issuance costs on issued shares related to SEPA agreement                       | $ |                      300,000 |   | $ |            |   |

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

<div align='center'>F-28

MEDICUS PHARMA LTD.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)</div>

1. Description of business

Medicus Pharma Ltd. (the "Company" or "Medicus Pharma"), formerly Interactive Capital Partners Corporation ("Interactive"), is a clinical stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.

The Company is a public limited Company originally incorporated pursuant to the provisions of the Business Corporations Act (Ontario) on April 30, 2008, as a private company named Interactive Capital Partners Corporation, with